全文获取类型
收费全文 | 418篇 |
免费 | 17篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 4篇 |
基础医学 | 56篇 |
临床医学 | 21篇 |
内科学 | 251篇 |
皮肤病学 | 2篇 |
神经病学 | 5篇 |
外科学 | 13篇 |
综合类 | 9篇 |
一般理论 | 1篇 |
预防医学 | 2篇 |
眼科学 | 3篇 |
药学 | 15篇 |
肿瘤学 | 55篇 |
出版年
2023年 | 1篇 |
2022年 | 1篇 |
2020年 | 5篇 |
2019年 | 7篇 |
2018年 | 8篇 |
2017年 | 7篇 |
2016年 | 9篇 |
2015年 | 7篇 |
2014年 | 10篇 |
2013年 | 16篇 |
2012年 | 29篇 |
2011年 | 31篇 |
2010年 | 17篇 |
2009年 | 8篇 |
2008年 | 23篇 |
2007年 | 23篇 |
2006年 | 13篇 |
2005年 | 28篇 |
2004年 | 23篇 |
2003年 | 26篇 |
2002年 | 19篇 |
2001年 | 20篇 |
2000年 | 30篇 |
1999年 | 28篇 |
1998年 | 7篇 |
1997年 | 2篇 |
1996年 | 3篇 |
1995年 | 5篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 5篇 |
1991年 | 4篇 |
1990年 | 3篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 5篇 |
1985年 | 2篇 |
1984年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
排序方式: 共有439条查询结果,搜索用时 15 毫秒
61.
Autoimmune conditions associated with primary biliary cirrhosis: response to ursodeoxycholic acid therapy 总被引:1,自引:0,他引:1
T.H. Zukowski M.D. R.A. Jorgensen R.N. E.R. Dickson M.D. K.D. Lindor M.D. 《The American journal of gastroenterology》1998,93(6):958-961
Objectives: A variety of autoimmune conditions occur in association with primary biliary cirrhosis. Among these conditions are sicca syndrome, Raynaud's phenomenon, arthritis, and Hashimoto's thyroiditis. Information is sparse regarding the prevalence and natural history of these conditions when associated with primary biliary cirrhosis and their response to ursodeoxycholic acid treatment. We evaluated the prevalence, natural history, and response to ursodeoxycholic acid therapy of these conditions coassociated with primary biliary cirrhosis.
Methods: One hundred-eighty patients with primary biliary cirrhosis, enrolled in a prospective randomized controlled trial of ursodeoxycholic acid (13–15 mg/kg/day), were included. Patients were assessed at study entry and annually.
Results: At entry, 77/180 patients (43%) had one of the four conditions, and 18/180 patients (10%) had two or more conditions. Sicca syndrome was the most common, occurring in 58/180 patients (32%). After 2 yr, there was no difference between the treatment groups with regard to resolution or spontaneous onset of these autoimmune features. Sicca syndrome was the most common spontaneously developing condition (9% per yr). Sicca syndrome was the most common associated autoimmune condition, present in one-third of our patients. The associated conditions tended to improve over time, with a low rate of spontaneously developing these conditions. Although ursodeoxycholic acid therapy leads to improvement in the underlying liver disease, it did not appear to influence either the development or resolution of these autoimmune features.
Conclusions: Although ursodeoxycholic acid is beneficial in the treatment of primary biliary cirrhosis, it had no measurable effect on the autoimmune conditions coassociated with the disease. 相似文献
Methods: One hundred-eighty patients with primary biliary cirrhosis, enrolled in a prospective randomized controlled trial of ursodeoxycholic acid (13–15 mg/kg/day), were included. Patients were assessed at study entry and annually.
Results: At entry, 77/180 patients (43%) had one of the four conditions, and 18/180 patients (10%) had two or more conditions. Sicca syndrome was the most common, occurring in 58/180 patients (32%). After 2 yr, there was no difference between the treatment groups with regard to resolution or spontaneous onset of these autoimmune features. Sicca syndrome was the most common spontaneously developing condition (9% per yr). Sicca syndrome was the most common associated autoimmune condition, present in one-third of our patients. The associated conditions tended to improve over time, with a low rate of spontaneously developing these conditions. Although ursodeoxycholic acid therapy leads to improvement in the underlying liver disease, it did not appear to influence either the development or resolution of these autoimmune features.
Conclusions: Although ursodeoxycholic acid is beneficial in the treatment of primary biliary cirrhosis, it had no measurable effect on the autoimmune conditions coassociated with the disease. 相似文献
62.
Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis 总被引:3,自引:0,他引:3
K.D. Lindor M.D. M.A. Lacerda M.D. R.A. Jorgensen R.N. C.K. DeSotel R.N. A.K. Batta Ph.D. G. Salen M.D. E.R. Dickson M.D. S.S. Rossi Ph.D. A.F. Hofmann M.D. 《The American journal of gastroenterology》1998,93(9):1498-1504
Objective: Ursodeoxycholic acid (UDCA) improves liver biochemistries and enriches the bile with UDCA in patients with primary biliary cirrhosis. The aim of this study was to determine whether the degree of enrichment of bile correlated with that of serum and whether either of these measures correlated with improvement in measures of liver disease.
Methods: In a randomized study, biliary and serum bile acid analyses were performed at entry and after 2 yr of UDCA or placebo.
Results: The percentage of ursodeoxycholic acid in bile increased by 42% in the UDCA group ( n = 61 ) compared with 8% in the placebo group ( n = 57 ) ( p < 0.0001 ). Measurement of serum bile acids in 32 patients (18 ursodeoxycholic acid, 14 placebo) indicated that at 2 yr, ursodeoxycholic acid comprised 65% of serum bile acids in the treated group and 7% in the placebo group. Agreement between bile and serum was fair ( r = 0.75 , p ≤ 0.00002 ) because in some patients, plasma but not biliary bile acids were enriched with UDCA. Changes in biliary ursodeoxycholic acid correlated significantly but weakly with the changes in serum alkaline phosphatase, AST, bilirubin, and in Mayo risk score. Correlations between changes in serum bile acid composition and biochemical measures of disease activity were even weaker.
Conclusion: The measurement of biliary bile acids is superior to that of serum bile acids for assessing the compliance and changes in the circulating bile acids in patients receiving ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Furthermore, measures to further increase the proportion of ursodeoxycholic acid in circulating bile acids should be explored. 相似文献
Methods: In a randomized study, biliary and serum bile acid analyses were performed at entry and after 2 yr of UDCA or placebo.
Results: The percentage of ursodeoxycholic acid in bile increased by 42% in the UDCA group ( n = 61 ) compared with 8% in the placebo group ( n = 57 ) ( p < 0.0001 ). Measurement of serum bile acids in 32 patients (18 ursodeoxycholic acid, 14 placebo) indicated that at 2 yr, ursodeoxycholic acid comprised 65% of serum bile acids in the treated group and 7% in the placebo group. Agreement between bile and serum was fair ( r = 0.75 , p ≤ 0.00002 ) because in some patients, plasma but not biliary bile acids were enriched with UDCA. Changes in biliary ursodeoxycholic acid correlated significantly but weakly with the changes in serum alkaline phosphatase, AST, bilirubin, and in Mayo risk score. Correlations between changes in serum bile acid composition and biochemical measures of disease activity were even weaker.
Conclusion: The measurement of biliary bile acids is superior to that of serum bile acids for assessing the compliance and changes in the circulating bile acids in patients receiving ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Furthermore, measures to further increase the proportion of ursodeoxycholic acid in circulating bile acids should be explored. 相似文献
63.
Dusica Babovic-Vuksanovic Virginia V. Michels Mark E. Law Richard Bailey William A. Wyatt Noralane M. Lindor Syed M. Jalal 《American journal of medical genetics. Part A》1999,84(4):357-360
Buccal smear analysis is a noninvasive, fast, and relatively inexpensive diagnostic method. It is used commonly where rapid gender identification is necessary or, more recently, for detection of aneusomy, microdeletion syndromes, and a variety of polymerase chain reaction–based molecular genetic tests. Previously we have shown that maternal cells can contaminate buccal smears taken from breast-fed infants, resulting in difficulty with test interpretation. The aim of this study was to determine optimal timing and technique for buccal smear collection in breast-fed infants in order to avoid diagnostic errors. We analyzed prospectively 50 breast-fed male infants for presence of cells with XX signal pattern from buccal mucosa scrapings at different times after breast feeding. The efficiency of mucosal cleaning on elimination of maternal cells was evaluated by comparing the proportion of XX cells before and after wiping of buccal mucosa with a cotton swab. Maternal cells were present in 23 of 48 (47.9%) samples collected within 5 min of feeding. The proportion of XX signal pattern was significantly (P = 0.001) reduced in samples collected at 30 min (8/48, P = 0.001) and ≥60 min (2/29, P = 0.0002) after feeding. Mucosal cleaning prior to smear collection significantly decreased the number of XX positive samples from 23 of 48 to 10 of 48 (P = 0.002). Buccal smears should not be obtained in nursing neonates until at least 60 min after breast feeding. In addition, prior to sample collection, buccal mucosa should be cleaned thoroughly with a cotton swab applicator. The same guidelines are applicable to older nursing infants. Am. J. Med. Genet. 84:357–360, 1999. © 1999 Wiley-Liss, Inc. 相似文献
64.
Osorio A Milne RL Alonso R Pita G Peterlongo P Teulé A Nathanson KL Domchek SM Rebbeck T Lasa A Konstantopoulou I Hogervorst FB Verhoef S van Dooren MF Jager A Ausems MG Aalfs CM van Asperen CJ Vreeswijk M Waisfisz Q Van Roozendaal CE Ligtenberg MJ;HEBON;EMBRACE Easton DF Peock S Cook M Oliver CT Frost D Curzon B Evans DG Lalloo F Eeles R Izatt L Davidson R Adlard J Eccles D Ong KR Douglas F Downing S Brewer C Walker L Nevanlinna H Aittomäki K Couch FJ Fredericksen Z Lindor NM Godwin A Isaacs C 《British journal of cancer》2011,104(8):1356-1361
Background:
Single-nucleotide polymorphisms (SNPs) in genes involved in DNA repair are good candidates to be tested as phenotypic modifiers for carriers of mutations in the high-risk susceptibility genes BRCA1 and BRCA2. The base excision repair (BER) pathway could be particularly interesting given the relation of synthetic lethality that exists between one of the components of the pathway, PARP1, and both BRCA1 and BRCA2. In this study, we have evaluated the XRCC1 gene that participates in the BER pathway, as phenotypic modifier of BRCA1 and BRCA2.Methods:
Three common SNPs in the gene, c.-77C>T (rs3213245) p.Arg280His (rs25489) and p.Gln399Arg (rs25487) were analysed in a series of 701 BRCA1 and 576 BRCA2 mutation carriers.Results:
An association was observed between p.Arg280His-rs25489 and breast cancer risk for BRCA2 mutation carriers, with rare homozygotes at increased risk relative to common homozygotes (hazard ratio: 22.3, 95% confidence interval: 14.3–34, P<0.001). This association was further tested in a second series of 4480 BRCA1 and 3016 BRCA2 mutation carriers from the Consortium of Investigators of Modifiers of BRCA1 and BRCA2.Conclusions and inte
No evidence of association was found when the larger series was analysed which lead us to conclude that none of the three SNPs are significant modifiers of breast cancer risk for mutation carriers. 相似文献65.
Win AK Dowty JG English DR Campbell PT Young JP Winship I Macrae FA Lipton L Parry S Young GP Buchanan DD Martínez ME Jacobs ET Ahnen DJ Haile RW Casey G Baron JA Lindor NM Thibodeau SN Newcomb PA Potter JD Le Marchand L Gallinger S Hopper JL Jenkins MA 《British journal of cancer》2011,105(1):162-169
Background:
Carriers of germline mutations in DNA mismatch repair (MMR) genes have a high risk of colorectal cancer (CRC), but the modifiers of this risk are not well established. We estimated an association between body mass index (BMI) in early adulthood and subsequent risk of CRC for carriers and, as a comparison, estimated the association for non-carriers.Methods:
A weighted Cox regression was used to analyse height and weight at 20 years reported by 1324 carriers of MMR gene mutations (500 MLH1, 648 MSH2, 117 MSH6 and 59 PMS2) and 1219 non-carriers from the Colon Cancer Family Registry.Results:
During 122 304 person-years of observation, we observed diagnoses of CRC for 659 carriers (50%) and 36 non-carriers (3%). For carriers, the risk of CRC increased by 30% for each 5 kg m–2 increment in BMI in early adulthood (hazard ratio, HR: 1.30; 95% confidence interval, CI: 1.08–1.58; P=0.01), and increased by 64% for non-carriers (HR: 1.64; 95% CI: 1.02–2.64; P=0.04) after adjusting for sex, country, cigarette smoking and alcohol drinking (and the MMR gene that was mutated in carriers). The difference in HRs for carriers and non-carriers was not statistically significant (P=0.50). For MLH1 and PMS2 (MutLα heterodimer) mutation carriers combined, the corresponding increase was 36% (HR: 1.36; 95% CI: 1.05–1.76; P=0.02). For MSH2 and MSH6 (MutSα heterodimer) mutation carriers combined, the HR was 1.26 (95% CI: 0.96–1.65; P=0.09). There was no significant difference between the HRs for MutLα and MutSα heterodimer carriers (P=0.56).Conclusion:
Body mass index in early adulthood is positively associated with risk of CRC for MMR gene mutation carriers and non-carriers. 相似文献66.
Win AK Cleary SP Dowty JG Baron JA Young JP Buchanan DD Southey MC Burnett T Parfrey PS Green RC Le Marchand L Newcomb PA Haile RW Lindor NM Hopper JL Gallinger S Jenkins MA 《International journal of cancer. Journal international du cancer》2011,129(9):2256-2262
Cancer risks for a person who has inherited a MUTYH mutation from only one parent (monoallelic mutation carrier) are uncertain. Using the Colon Cancer Family Registry and Newfoundland Familial Colon Cancer Registry, we identified 2,179 first- and second-degree relatives of 144 incident colorectal cancer (CRC) cases who were monoallelic or biallelic mutation carriers ascertained by sampling population complete cancer registries in the United States, Canada and Australia. Using Cox regression weighted to adjust for sampling on family history, we estimated that the country-, age- and sex-specific standardized incidence ratios (SIRs) for monoallelic mutation carriers, compared to the general population, were: 2.04 (95% confidence interval, CI 1.56-2.70; p < 0.001) for CRC, 3.24 (95%CI 2.18-4.98; p < 0.001) for gastric cancer, 3.09 (95%CI 1.07-12.25; p = 0.07) for liver cancer and 2.33 (95%CI 1.18-5.08; p = 0.02) for endometrial cancer. Age-specific cumulative risks to age 70 years, estimated using the SIRs and US population incidences, were: for CRC, 6% (95%CI 5-8%) for men and 4% (95%CI 3-6%) for women; for gastric cancer, 2% (95%CI 1-3%) for men and 0.7% (95%CI 0.5-1%) for women; for liver cancer, 1% (95%CI 0.3-3%) for men and 0.3% (95%CI 0.1-1%) for women and for endometrial cancer, 4% (95%CI 2-8%). There was no evidence of increased risks for cancers of the brain, pancreas, kidney, lung, breast or prostate. Monoallelic MUTYH mutation carriers with a family history of CRC, such as those identified from screening multiple-case CRC families, are at increased risk of colorectal, gastric, endometrial and possibly liver cancers. 相似文献
67.
Cicek MS Lindor NM Gallinger S Bapat B Hopper JL Jenkins MA Young J Buchanan D Walsh MD Le Marchand L Burnett T Newcomb PA Grady WM Haile RW Casey G Plummer SJ Krumroy LA Baron JA Thibodeau SN 《The Journal of molecular diagnostics : JMD》2011,13(3):271-281
The detection of defective mismatch repair (MMR), as assessed by the presence of tumor microsatellite instability (MSI) and/or loss of MMR protein expression by IHC, has been useful for risk assessment, prognosis, and prediction of treatment in patients with colorectal cancer. We analyzed tumors for the presence of defective MMR from 5927 Colorectal Cancer Family Registry patients recruited at six international consortium sites. We evaluated the appropriate percentage instability cutoff used to distinguish the three MSI phenotypes [ie, stable (MSS), low instability (MSI-L), and high instability (MSI-H)]; the sensitivity, specificity, and performance characteristics of individual markers; and the concordance between MSI and IHC phenotypes. Guided by the results of the IHC testing, our findings indicate that the distinction between an MSI-H phenotype from a low-instability or MSS phenotype can best be accomplished by using a cutoff of 30% or greater of the markers showing instability. The sensitivity and specificity of the mononucleotide markers were higher than those of the dinucleotide markers. Specifically, BAT26 and BAT25 had the highest sensitivity (94%) and specificity (98%), and the use of mononucleotide markers alone identified 97% of the MSI-H cases correctly. As expected, the presence of MSI-H correlated with an older age of diagnosis, the presence of tumor in the proximal colon, and female sex. 相似文献
68.
69.
70.